2023 ASCO Takeaways

The 2023 American Society of Clinical Oncology Annual Meeting featured five days of research presentations, educational sessions, posters, and networking events. The amount of research presented can be overwhelming, so we asked Dr. Stephanie Graff to break down the key takeaways for people who’ve been diagnosed with breast cancer. Listen to the episode to hear Dr. Graff explain: the results of the NATALEE trial on Kisqali (chemical name: ribociclib) for early-stage breast cancer a meta-analysis showing ovarian suppression definitely reduces the risk of recurrence for pre-menopausal women diagnosed with breast cancer a poster showing that diclofenac (brand names: Flector, Cambia, Zipsor), a non-steroidal anti-inflammatory medicine, in a topical gel form seems to help ease hand-foot syndrome caused by the chemotherapy medicine Xeloda (chemical name: capecitabine)

There are no comments yet.

Please log in to write the first comment.